Evaluation of Novel CD8 T Regulatory Cells in Patients with
Multiple Myeloma at Baseline and after Len-Dex Treatment

a 2013

Evaluation of Novel CD8 T Regulatory Cells in Patients with Multiple Myeloma at Baseline and after Len-Dex Treatment

MUTHU RAJA, Karthick Raja; Lucie ŘÍHOVÁ; Jana PELCOVÁ; Lenka ZAHRADOVÁ; Roman HÁJEK et al.

Základní údaje

Originální název

Evaluation of Novel CD8 T Regulatory Cells in Patients with Multiple Myeloma at Baseline and after Len-Dex Treatment

Autoři

MUTHU RAJA, Karthick Raja; Lucie ŘÍHOVÁ; Jana PELCOVÁ; Lenka ZAHRADOVÁ a Roman HÁJEK

Vydání

14th International Myeloma Workshop, 2013

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.929

Označené pro přenos do RIV

Organizační jednotka

Lékařská fakulta

ISSN

Změněno: 20. 5. 2013 12:35, Mgr. Anna Potáčová, Ph.D.

Anotace

V originále

Regulatory T cells (Tregs) play a significant role in maintaining immune homeostasis in healthy individuals. In cancer patients Tregs were considered as immune suppressors due to their expansion. In multiple myeloma (MM), we and others have shown the suppressive role of CD4 Tregs. In the present study, we investigated novel regulatory cells expressing CD8 marker (CD8 Tregs) in MM patients at baseline and after lenalidomide plus dexamethasone (LD) treatment. Peripheral blood (PB) samples were collected at baseline and after 4 cycles of LD treatment from a cohort of 16 MM patients. As a control group, 10 healthy donors (HDs) PB samples were also collected. CD8 Tregs were identified as CD8+CD25hi+FoxP3+. These CD8 Tregs share similar phenotypic features of CD4 Tregs in terms of expression of CD127 and CTLA-4. Baseline CD8 Treg numbers were significantly increased in MM patients compared to HDs (median: 0.51% vs. 0.12%; P=0.01), but no other significant differences were observed with respect to total lymphocytes, CD4 and CD8 T cell numbers. Analysis of CD8 Tregs at baseline and after LD treatment clearly showed a significant increase in CD8 Treg numbers after LD treatment (median: 1.35% vs. 0.51%; P=0.01). Functional studies revealed that CD8 Tregs from MM patients at baseline and after LD treatment were suppressive (inhibited CD4 T cell proliferation and IFN-gamma secretion) as similar to CD8 Tregs from HDs. These findings suggest that increase in CD8 Treg numbers might promote immune impairment, thereby, predisposing MM patients to infections and disease progression.

Citovat

MUTHU RAJA, Karthick Raja; Lucie ŘÍHOVÁ; Jana PELCOVÁ; Lenka ZAHRADOVÁ a Roman HÁJEK. Evaluation of Novel CD8 T Regulatory Cells in Patients with Multiple Myeloma at Baseline and after Len-Dex Treatment. In 14th International Myeloma Workshop. 2013. ISSN 2152-2650.

@proceedings{1107533,
   author = {Muthu Raja, Karthick Raja and Říhová, Lucie and Pelcová, Jana and Zahradová, Lenka and Hájek, Roman},
   booktitle = {14th International Myeloma Workshop},
   language = {eng},
   title = {Evaluation of Novel CD8 T Regulatory Cells in Patients with Multiple Myeloma at Baseline and after Len-Dex Treatment},
   year = {2013}
}

TY  - CONF
ID  - 1107533
AU  - Muthu Raja, Karthick Raja - Říhová, Lucie - Pelcová, Jana - Zahradová, Lenka - Hájek, Roman
PY  - 2013
TI  - Evaluation of Novel CD8 T Regulatory Cells in Patients with Multiple Myeloma at Baseline and after Len-Dex Treatment
N2  - Regulatory T cells (Tregs) play a significant role in maintaining immune homeostasis in healthy individuals. In cancer patients Tregs were considered as immune suppressors due to their expansion. In multiple myeloma (MM), we and others have shown the suppressive role of CD4 Tregs. In the present study, we investigated novel regulatory cells expressing CD8 marker (CD8 Tregs) in MM patients at baseline and after lenalidomide plus dexamethasone (LD) treatment. Peripheral blood (PB) samples were collected at baseline and after 4 cycles of LD treatment from a cohort of 16 MM patients. As a control group, 10 healthy donors (HDs) PB samples were also collected. CD8 Tregs were identified as CD8+CD25hi+FoxP3+. These CD8 Tregs share similar phenotypic features of CD4 Tregs in terms of expression of CD127 and CTLA-4. Baseline CD8 Treg numbers were significantly increased in MM patients compared to HDs (median: 0.51% vs. 0.12%; P=0.01), but no other significant differences were observed with respect to total lymphocytes, CD4 and CD8 T cell numbers. Analysis of CD8 Tregs at baseline and after LD treatment clearly showed a significant increase in CD8 Treg numbers after LD treatment (median: 1.35% vs. 0.51%; P=0.01). Functional studies revealed that CD8 Tregs from MM patients at baseline and after LD treatment were suppressive (inhibited CD4 T cell proliferation and IFN-gamma secretion) as similar to CD8 Tregs from HDs. These findings suggest that increase in CD8 Treg numbers might promote immune impairment, thereby, predisposing MM patients to infections and disease progression.
ER  -

MUTHU RAJA, Karthick Raja; Lucie ŘÍHOVÁ; Jana PELCOVÁ; Lenka ZAHRADOVÁ a Roman HÁJEK. Evaluation of Novel CD8 T Regulatory Cells in Patients with Multiple Myeloma at Baseline and after Len-Dex Treatment. In \textit{14th International Myeloma Workshop}. 2013. ISSN~2152-2650.

Přehled o publikaci